Cite
HARVARD Citation
Ogasawara, S. et al. (2022). Durvalumab with or without tremelimumab combined with particle therapy for advanced hepatocellular carcinoma with macrovascular invasion: protocol for the DEPARTURE phase Ib trial. BMJ open. 12 (4), p. . [Online].